Skip to main content
logo
Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
28.13
-0.52 (-1.82%)
At close: Sep 5, 2025, 4:00 PM
28.50
+0.37 (1.32%)
After-hours: Sep 5, 2025, 5:29 PM EDT

Apellis Pharmaceuticals Revenue by Segment

Period EndingJun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021
Product
689.03M696.78M709.95M657.44M580.05M490.56M366.28M247.28M
Product Growth
18.79%42.04%93.83%165.87%249.90%434.47%462.71%352.49%
Collaboration License and Other
65.62M79.06M71.41M57.78M48.74M33.51M30.31M25.60M
Collaboration License and Other Growth
34.64%135.91%135.62%125.73%159.80%137.61%193.41%-56.17%

Product Revenue by Segment

Period EndingJun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021
Syfovre
600.59M604.58M611.85M558.35M481.67M394.39M275.28M--------
Syfovre Growth
24.69%53.30%122.26%------------
Empaveli
88.47M92.22M98.13M99.13M98.42M96.21M91.04M86.34M
Empaveli Growth
-10.11%-4.15%7.79%14.81%22.81%30.91%39.72%57.93%
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.